Still suspended
+------------------------------------------------------------------------------+
BN 04/04 13:02 *MEDA CONFIRMS MYLAN INDICATIVE APPROACH, SAYS REJECTED PROPOSAL BFW 04/04 13:01 *MEDA SAYS DISCUSSIONS TERMINATED WITHOUT FURTHER ACTIONS BN 04/04 13:01 *MEDA: TALKS BETWEEN MEDA, MYLAN HAVE BEEN TERMINATED BN 04/04 13:00 *MEDA CONTACTED BY MYLAN REGARDING INDICATIVE MERGER PROPOSAL BN 04/04 13:00 *MEDA SAYS DISCUSSIONS TERMINATED WITHOUT FURTHER ACTIONS BFW 04/04 13:00 *MEDA: DECIDED TO REJECT MYLAN PROPOSAL BN 04/04 13:00 *MEDA HEREBY CONFIRMS THAT IT HAS BEEN CONTACTED BY MYLAN BN 04/04 13:00 *MEDA: MYLAN CONTACTED RE INDICATIVE PROPOSAL TO COMBINE BN 04/04 13:00 *MEDA: DECIDED TO REJECT MYLAN PROPOSAL BN 04/04 13:00 *MEDA SAYS TALKS ENDED WITHOUT FURTHER ACTIONS BN 04/04 13:00 *MEDA: DECIDED TO REJECT PROPOSAL BN 04/04 13:00 *MEDA CONFIRMS THAT IT WAS CONTACTED BY MYLAN BN 04/04 13:00 *MEDA: CONFIRMS THAT IT CONTACTED BY MYLAN BN 04/04 13:00 *MEDA CONFIRMS THAT IT CONTACTED BY MYLAN BN 04/04 13:00 *MEDA: STATEMENT BY BOARD OF DIRECTORS OF MEDA BN 04/04 13:00 *MEDA: STATEMENT BY BOARD OF MEDA
+------------------------------------------------------------------------------+
MEDA: Statement by the Board of Directors of Meda 2014-04-04 13:00:21.875 GMT
This statement is made by the Board of Directors (the ”Board”) of Meda AB (publ) (”Meda”) pursuant to the Securities Markets Act and/or the Financial Instruments Trading act.
The Board hereby confirms that it has been contacted by Mylan, Inc. (“Mylan”) regarding an indicative proposal to combine the two businesses. The Board has convened and has decided to reject the proposal. All continued discussions between Meda and Mylan have been terminated without further actions.
The Board of Directors Meda AB (publ)
For further inquiries, please contact:
Paula Treutiger, Investor Relations ph: +46 733-666 599
paula.treutiger@meda.se
Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 4, 2014, at 15:00 CET.
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This information was brought to you by Cision http://news.cision.com The following files are available for download: http://mb.cision.com/Main/357/9564239/229511.pdf Statement by the Board of Directors of Meda
Provider ID: 64LS17S7
-0- Apr/04/2014 13:00 GMT